Cell Death Mechanism Group, Institute for Ophthalmic Research, University of Tübingen, 72076 Tübingen, Germany.
Graduate Training Centre of Neuroscience, University of Tübingen, 72076 Tübingen, Germany.
Biomolecules. 2022 Mar 15;12(3):455. doi: 10.3390/biom12030455.
Inherited retinal degenerations (IRDs) are a group of blinding diseases, typically involving a progressive loss of photoreceptors. The IRD pathology is often based on an accumulation of cGMP in photoreceptors and associated with the excessive activation of calpain and poly (ADP-ribose) polymerase (PARP). Inhibitors of calpain or PARP have shown promise in preventing photoreceptor cell death, yet the relationship between these enzymes remains unclear. To explore this further, organotypic retinal explant cultures derived from wild-type and IRD-mutant mice were treated with inhibitors specific for calpain, PARP, and voltage-gated Ca channels (VGCCs). The outcomes were assessed using in situ activity assays for calpain and PARP and immunostaining for activated calpain-2, poly (ADP-ribose), and cGMP, as well as the TUNEL assay for cell death detection. The IRD models included the mutant mouse and double-mutant mice, which lack the beta subunit of the rod cyclic nucleotide-gated (CNG) channel and are partially protected from degeneration. We confirmed that an inhibition of either calpain or PARP reduces photoreceptor cell death in retina. However, while the activity of calpain was decreased by the inhibition of PARP, calpain inhibition did not alter the PARP activity. A combination treatment with calpain and PARP inhibitors did not synergistically reduce cell death. In the slow degeneration of * double mutant, VGCC inhibition delayed photoreceptor cell death, while PARP inhibition did not. Our results indicate that PARP acts upstream of calpain and that both are part of the same degenerative pathway in -dependent photoreceptor degeneration. While PARP activation may be associated with CNG channel activity, calpain activation is linked to VGCC opening. Overall, our data highlights PARP as a target for therapeutic interventions in IRD-type diseases.
遗传性视网膜退行性病变(IRDs)是一组致盲疾病,通常涉及感光细胞的进行性丧失。IRD 病理学通常基于感光细胞中环鸟苷酸(cGMP)的积累,并与钙蛋白酶和多聚(ADP-核糖)聚合酶(PARP)的过度激活有关。钙蛋白酶或 PARP 的抑制剂已显示出在预防感光细胞死亡方面有希望,但这两种酶之间的关系仍不清楚。为了进一步探讨这一问题,从野生型和 IRD 突变型小鼠中分离出的器官型视网膜外植体培养物用钙蛋白酶、PARP 和电压门控钙通道(VGCC)的特异性抑制剂进行处理。通过原位活性测定、钙蛋白酶和 PARP 的免疫染色、活性钙蛋白酶-2、多聚(ADP-核糖)和 cGMP 的免疫染色以及 TUNEL 测定法检测细胞死亡来评估结果。IRD 模型包括突变型小鼠和双突变型小鼠,它们缺乏杆状环核苷酸门控(CNG)通道的β亚基,并且部分免受变性的影响。我们证实,钙蛋白酶或 PARP 的抑制均可减少视网膜变性中的感光细胞死亡。然而,虽然 PARP 的抑制降低了钙蛋白酶的活性,但钙蛋白酶的抑制并未改变 PARP 的活性。钙蛋白酶和 PARP 抑制剂的联合治疗并未协同降低细胞死亡。在*双突变体的缓慢变性中,VGCC 抑制延迟了感光细胞的死亡,而 PARP 抑制则没有。我们的结果表明,PARP 位于钙蛋白酶的上游,两者都是独立的感光细胞变性中相同变性途径的一部分。虽然 PARP 的激活可能与 CNG 通道的活性有关,但钙蛋白酶的激活与 VGCC 的开放有关。总之,我们的数据突出了 PARP 作为治疗干预 IRD 型疾病的靶点。